{
    "clinical_study": {
        "@rank": "154527", 
        "arm_group": [
            {
                "arm_group_label": "Bravelle & Menopur Agonist Long Protocol", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation."
            }, 
            {
                "arm_group_label": "Bravelle & Menopur Antagonist Protocol", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if utilizing GnRH antagonists versus agonist long\n      protocol during controlled ovarian stimulation (COH) with human-derived gonadotropins for\n      assisted reproduction affects IVF outcome, peak estradiol level, and duration of\n      stimulation."
        }, 
        "brief_title": "Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Fertility", 
        "detailed_description": {
            "textblock": "No detailed description"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages 21-40 (inclusive up to 41)\n\n          -  Day 2-4 FSH < or equal to 10\n\n          -  Antimullerian Hormone (AMH) greater than or equal to 1.0\n\n          -  Between 5 and 20 antral follicles on day 2-4\n\n          -  Body Mass Index (BMI)>or equal to 18 and < or equal to 32\n\n        Exclusion Criteria:\n\n          -  Smokers\n\n          -  Polycystic Ovarian Disease\n\n          -  Endometriosis greater than Stage I\n\n          -  Testicular aspirated sperm"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669291", 
            "org_study_id": "MLFC-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bravelle & Menopur Agonist Long Protocol", 
                    "Bravelle & Menopur Antagonist Protocol"
                ], 
                "description": "Bravelle and Menopur are used for controlled ovarian stimulation (COH)", 
                "intervention_name": "Bravelle and Menopur", 
                "intervention_type": "Drug", 
                "other_name": "Bravelle and Menopur"
            }, 
            {
                "arm_group_label": "Bravelle & Menopur Agonist Long Protocol", 
                "description": "Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.", 
                "intervention_name": "Agonist", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Leuprolide Acetate", 
                    "Lupron"
                ]
            }, 
            {
                "arm_group_label": "Bravelle & Menopur Antagonist Protocol", 
                "description": "Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.", 
                "intervention_name": "Antagonist", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ganirelix acetate", 
                    "cetrorelix acetate"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Ganirelix", 
                "Cetrorelix", 
                "Menotropins", 
                "Leuprolide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bryn Mawr", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19010"
                }, 
                "name": "Main Line Fertility Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of GnRH Antagonist Protocol vs Agonist Long Protocol During Controlled Hyperstimulation (COH)for Assisted Reproduction on IVF Outcome, Peak Estradiol Level, and Duration of Stimulation.", 
        "overall_official": [
            {
                "affiliation": "Main Line Fertility Center", 
                "last_name": "Michael J Glassner, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Main Line Fertility Center", 
                "last_name": "Sharon H. Anderson, Ph.D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine if COH in IVF patients using Bravelle & Menopur with antagonists results in improved or equal IVF results compared to patients using agonist.", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "reference": [
            {
                "PMID": "11789740", 
                "citation": "Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2001 Nov;265(4):175-82."
            }, 
            {
                "PMID": "11163814", 
                "citation": "Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB; North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001 Jan;75(1):38-45."
            }, 
            {
                "PMID": "10985616", 
                "citation": "Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethm\u00fcller-Winzen H, Sch\u00fcler A, Engel W, Diedrich K. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet. 2000 Jul;264(1):29-32."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determined if COH in IVF patients using Bravelle & Menopur with antagonists results in lower peak estradiol levels compared to agonist", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "measure": "To determine if COH patients using Bravelle & Menopur with antagonist  antagonists results inn shorter period of stimulation compared with agonist.", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Main Line Fertility Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Main Line Fertility Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}